TNFRSF17 and plasma cell myeloma: Interestingly, B cell maturation antigen (BCMA) directed CAR-T cells in combination with crenigacestat appears to demonstrate appreciable anti-cancer efficacy in patients with multiple myeloma (NCT03502577) [332].